Identifying Treatment Effect Heterogeneity with Bayesian Hierarchical Adjustable Random Partition in Adaptive Enrichment Trials
用贝叶斯层级可调随机分区识别自适应富集试验中的治疗效应异质性AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要围绕临床干预的组别治疗效应和效应异质性展开,并在自适应试验中应用,因此最直接对应因果推断方向。
用贝叶斯层级可调随机分区识别自适应富集试验中的治疗效应异质性AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
Treatment effect heterogeneity refers to the systematic variation in treatment effects across subgroups. There is an increasing need for clinical trials that aim to investigate treatment effect heterogeneity and estimate subgroup-specific responses. While several statistical methods have been proposed to address this problem, existing partitioning-based methods often depend on auxiliary analysis, overlook model uncertainty, or impose inflexible borrowing strength. We propose the Bayesian Hierarchical Adjustable Random Partition (BHARP) model, a self-contained framework that applies a finite mixture model with an unknown number of components to explore the partition space accounting for model uncertainty. The BHARP model jointly estimates subgroup-specific effects and the heterogeneity patterns, and adjusts the borrowing strengths based on within-cluster cohesion without requiring manual calibration. Posterior sampling is performed via a custom reversible-jump Markov chain Monte Carlo sampler tailored to partitioning-based information borrowing in clinical trials. Simulation studies across a range of treatment effect heterogeneity patterns show that the BHARP model achieves better accuracy and precision compared to conventional and advanced methods. We showcase the utilities of the BHARP model in the context of a multi-arm adaptive enrichment trial investigating physical activity interventions in patients with type 2 diabetes.